TNF and inflammatory bowel disease: Although treatment of inflammatory bowel disease (IBD) has significantly improved with the introduction of monoclonal antibodies against tumor necrosis factor (anti-TNF) and α4β7 integrin (vedolizumab), a considerable proportion of patients either fail to respond or lose response over time to these agents [6].